Publications

Loper Bright bringing more scrutiny, uncertainty to US agencies

Quoted, BioWorld

Chad Landmon, Hatch-Waxman & Biologics Chair, discusses how the Loper Bright ruling might impact the life sciences industry beyond HHS and the FDA.